After a thorough and comprehensive review of proposals received from suppliers of viral marker testing platforms and assays, CTS has decided to convert to the Ortho VERSEIA Integrated Processor (VIP) viral marker testing platform and associated assays in January 2021. An exact conversion date will be provided when available. We are confident that the VERSIA system will allow us to continue delivering on our commitment to support our clients in their life-saving mission.
Read all about it on the Communication page by clicking this link: Communications
CTS lab staff recently participated in a Kaizen and determined emailed Daily Shipment Schedules to b...
The CTS Medical Advisory Board recently agreed upon a revision to our standard testing algorithm. Th...
Dr. Buff Mair is the new CTS Medical Director and replaces Dr. German Leparc who retired at the begi...
Reminder - Dr. Buff Mair is the new CTS Medical Director. Several of the CTS client forms specify li...
On July 6, 2018 the FDA released an industry guidance document for transitioning from individual to ...
The FDA Guidance ZIKV video for the webinar held on 08/15/18 has been posted in the Wh...